Skip to main content
Fig. 7 | Cell Communication and Signaling

Fig. 7

From: Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

Fig. 7

Single-cell analysis of AKT and FAK pathway activation does not reveal the HER-dependent differential sensitivity or drug synergy of HCC1954 cells to pan-HER and c-MET inhibitor combinations identified by CELsignia. HCC1954 cells were treated with c-MET (tepotinib) and pan-HER (neratinib) inhibitors, either singly or in combination, at the doses indicated for 16 h as described in Fig. 6 and then analyzed by intracellular phospho-flow cytometry. a, b The mean and standard deviation of levels of pAKT and pFAK in gated live cells following drug treatment from two experiments is shown. c Cells were treated with increasing doses of tepotinib or neratinib, administered singly or in combination as indicated, and analyzed for pAKT and pFAK expression patterns within single cells. At least 10,000 events were acquired per sample and data shown is representative of two experiments

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X